DrugPatentWatch Database Preview
Par Pharm Inc Company Profile
What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?
There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.
There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-three supplementary protection certificates in eleven countries.
Summary for Par Pharm Inc
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 27 |
| Ingredients: | 27 |
| NDAs: | 28 |
Drugs and US Patents for Par Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm Inc | DEXMETHYLPHENIDATE HYDROCHLORIDE | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 202842-005 | Nov 30, 2016 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Par Pharm Inc | MORPHINE SULFATE | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 200812-001 | Nov 10, 2011 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Par Pharm Inc | DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | doxylamine succinate; pyridoxine hydrochloride | TABLET, DELAYED RELEASE;ORAL | 208518-001 | Dec 6, 2017 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Par Pharm Inc | PHENOXYBENZAMINE HYDROCHLORIDE | phenoxybenzamine hydrochloride | CAPSULE;ORAL | 204522-001 | Jan 24, 2017 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Par Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 5,482,963 | ➤ Try a Free Trial |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 5,612,367 | ➤ Try a Free Trial |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 6,143,775 | ➤ Try a Free Trial |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 4,859,692 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
International Patents for Par Pharm Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 5378788 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2006115626 | ➤ Try a Free Trial |
| China | 101163679 | ➤ Try a Free Trial |
| European Patent Office | 1948613 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0443983/03 | Switzerland | ➤ Try a Free Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 00486 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
| 00152 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405 |
| 544 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
